4-苄基硫代苯硼酸 | 1005207-32-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 4-苄基硫代苯硼酸
• 中文别名: 4-苄硫基苯基硼酸
• 英文名称: (4-(benzylsulfanyl)phenyl)boronic acid
• 英文别名: (4-(Benzylthio)phenyl)boronic acid；(4-benzylsulfanylphenyl)boronic acid
• CAS: 1005207-32-8
• 化学式: C₁₃H₁₃BO₂S
• 分子量: 244.122
• InChiKey: ALXFJPATEOZQPF-UHFFFAOYSA-N

物化性质

• 熔点：
  148-149 °C(Solv: hexane (110-54-3))
• 沸点：
  435.4±55.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.66
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  65.8
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-Benzylthiophenylboronic Acid
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xi Irritant R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H319 Causes serious eye irritation.
Precautionary statement(s)
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 244,12 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-Benzylthiophenylboronic Acid
Eye Irrit. 2; H319 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-Benzylthiophenylboronic Acid
Xi, R36 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Eye Irrit. Eye irritation
H319 Causes serious eye irritation.
Full text of R-phrases referred to under sections 2 and 3
Xi Irritant
R36 Irritating to eyes.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-苄基硫代苯硼酸 在 ammonium hydroxide 、 四(三苯基膦)钯 、 1,3-二氯-5,5-二甲基海因 、 sodium carbonate 、 溶剂黄146 作用下， 以 甲醚 、 水 、 乙腈 为溶剂， 反应 17.58h， 生成 4-(2,2'-bipyridin-5-yl)benzenesulfonamide
  参考文献：
  名称：

  八面体铱（III）螺旋桨配合物对酶活性位点的手性识别

  摘要：

  手性双环金属化八面体有机铱 (III) 配合物旨在针对不同类别的酶，即碳酸酐酶、组蛋白脱乙酰酶和丝氨酸蛋白酶。选定配合物的立体选择性非外消旋合成用于研究螺旋桨型八面体金属配合物的对映异构体的酶活性位点的手性区分。鉴定了铱螺旋桨复合物与酶活性位点相互作用中可忽略的、适度的和显着的手性区分的情况。

  DOI：

  10.1002/ejic.201500087
• 作为产物：
  描述：

  在 盐酸 、 水 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 以2.2 g的产率得到4-苄基硫代苯硼酸
  参考文献：
  名称：

  卤素-锂交换与去质子化：芳基苄基硫醚的区域选择性单和双锂化。α，2-二硫代甲苯当量的一种简单方法

  摘要：

  研究了芳基苄基硫醚和烷基锂之间的卤素-锂交换和去质子反应。将得到的单和双锂化的中间体以良好的产率转化为相应的醛和硼或羧酸。发现二乙醚使邻位锂化的化合物稳定化，使其异构化为苄基衍生物。该过程很容易在低温下的THF中发生，并且是容易获得α，2-二硫代甲苯衍生物的途径，该衍生物在用CO 2处理后可以转化为二羧酸。

  DOI：

  10.1016/j.tetlet.2010.01.074

文献信息

• Alkylsulfanylphenyl Derivatives of Cytosine and 7-Deazaadenine Nucleosides, Nucleotides and Nucleoside Triphosphates: Synthesis, Polymerase Incorporation to DNA and Electrochemical Study
  作者：Hana Macíčková-Cahová、Radek Pohl、Petra Horáková、Luděk Havran、Jan Špaček、Miroslav Fojta、Michal Hocek

  DOI：10.1002/chem.201003496

  日期：2011.5.16

  halogenated nucleosides, nucleotides and nucleoside triphosphates derived from 5‐iodocytosine and 7‐iodo‐7‐deazaadenine with methyl‐, benzyl‐ and tritylsufanylphenylboronic acids gave the corresponding alkylsulfanylphenyl derivatives of nucleosides and nucleotides. The modified nucleoside triphosphates were incorporated into DNA by primer extension by using Vent(exo‐) polymerase. The electrochemical behaviour

  来自5-碘代胞嘧啶和7-碘代-7-脱氮杂腺嘌呤的卤代核苷，核苷酸和三磷酸核苷的Suzuki-Miyaura水溶液与甲基，苄基和三苯甲基磺酰基苯基硼酸的交叉偶联反应得到了相应的核苷和核苷酸烷基硫烷基苯基衍生物。使用Vent（exo-）聚合酶通过引物延伸将修饰的三磷酸核苷掺入DNA中。烷基硫烷基苯基核苷的电化学行为表明在电极上形成致密层。修饰的核苷酸和结合了苄基或三苯硫基硫烷基苯基的DNA在[Co（NH 3）6 ] 3+中产生信号铵缓冲液，归因于Brdička催化反应，具体取决于所施加的负电位。在这种介质中反复进行恒流计时电位扫描，发现其Brdička催化反应增强，这表明在该条件下，烷基硫烷基衍生物脱保护为游离硫醇。
• Polysubstituted Pyrimidines as mPGES‐1 Inhibitors: Discovery of Potent Inhibitors of PGE ₂ Production with Strong Anti‐inflammatory Effects in Carrageenan‐Induced Rat Paw Edema
  作者：Filip Kalčic、Viktor Kolman、Haresh Ajani、Zdeněk Zídek、Zlatko Janeba

  DOI：10.1002/cmdc.202000258

  日期：2020.8.5

  These compounds are sub‐micromolar inhibitors of PGE2 production (IC50 as low as 12 nM). In order to identify the molecular target of anti‐inflammatory pyrimidines, we performed extensive studies including enzymatic assays, homology modeling and docking. The difluorinated analogue simultaneously inhibits two key enzymes of the arachidonic acid cascade, namely mPGES‐1 and COX‐2, with mPGES‐1 inhibition

  我们报道了对多取代嘧啶进行的广泛的构效关系优化，从而发现了5-丁基-4-（4-苄氧基苯基）-6-苯基嘧啶-2-胺及其二氟类似物。这些化合物是PGE 2产生的亚微摩尔抑制剂（IC 50低至12 nM）。为了确定抗炎嘧啶的分子靶标，我们进行了广泛的研究，包括酶法测定，同源性建模和对接。二氟类似物同时抑制花生四烯酸级联的两个关键酶，即mPGES-1和COX-2，其中mPGES-1的抑制是主要的作用机理。研究的其他嘧啶类是有效的mPGES-1抑制剂，没有观察到对COX-1 / 2酶的抑​​制作用。此外，在急性炎症模型中，两种最有效的化合物在体内被证明是有效的，将角叉菜胶诱导的大鼠爪水肿抑制了36％和46％。这项研究的有希望的结果值得对所选的抗炎候选药物进行进一步的临床前评估。
• [EN] PYRIDAZINE DERIVATIVES AS EAAT2 ACTIVATORS<br/>[FR] DÉRIVÉS DE PYRIDAZINE EN TANT QU'ACTIVATEURS D'EAAT2
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2013019938A1

  公开（公告）日：2013-02-07

  Pyridazine derivatives that activate the excitatory amino acid transporter 2 (EAAT2), and methods of use thereof for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.

  吡啶二氮杂苯衍生物可激活兴奋性氨基酸转运蛋白2（EAAT2），以及利用这些方法治疗或预防与谷氨酸兴奋毒性相关的疾病、障碍和症状。
• Functionalization of some benzylthioarylboronic acids by benzylic lithiation of their N-butyldiethanolamine esters or lithium (triisopropoxy)borates
  作者：Krzysztof Durka、Tomasz Kliś、Janusz Serwatowski、Krzysztof Woźniak

  DOI：10.1002/aoc.1822

  日期：——

  The reaction of benzylthioarylboronic acids protected as N‐butyldiethanolamine esters or as triisopropoxyborates with organolithium bases or lithium diisopropylamide (LDA) has been investigated. The benzylic lithiation occurs selectively using LDA at − 68 °C. The stability of the resultant borio‐lithio intermediates is strongly influenced by the position of the boron atom in the phenyl ring. The reaction

  研究了被保护为N-丁基二乙醇胺酯或三异丙氧基硼酸酯的苄基硫代芳基硼酸与有机锂碱或二异丙基氨基化锂（LDA）的反应。在-68°C下使用LDA选择性地进行苄基锂化反应。所生成的硼亚硫基中间体的稳定性受到苯环中硼原子位置的强烈影响。与各种亲电试剂的反应提供了在苄基位置上取代的新的芳基硼酸。版权所有©2011 John Wiley＆Sons，Ltd.
• [EN] USP7 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF<br/>[FR] MOLÉCULES CHIMÉRIQUES CIBLANT LA SURVIE (SURTAC) SE LIANT À USP7 ET LEURS UTILISATIONS
  申请人：LOCKI THERAPEUTICS LTD

  公开号：WO2022148821A1

  公开（公告）日：2022-07-14

  Chimeric molecules that include a USP7 binding domain and uses thereof for deubiquitinating a ubiquitinylated protein, and or for treating a disease in a subject in need are provided herein. Further, Survival-Targeting Chimeric (SURTAC) molecules that include a USP7 binding domain linked to a target protein binding domain are disclosed herein, as are their uses for deubiquitination and treating disease. In some instances, the target protein is a ubiquitinylated protein, wherein a bound USP7 enzyme may proteolytically remove ubiquitin from the target ubiquitinylated protein.

  本文提供了包含USP7结合域的嵌合分子及其用途，用于去泛素化泛素化蛋白质或治疗需要的主体的疾病。此外，本文还公开了包括USP7结合域连接到目标蛋白质结合域的Survival-TArgeting Chimeric（SURTAC）分子及其用途，用于去泛素化和治疗疾病。在某些情况下，目标蛋白质是泛素化蛋白质，其中结合的USP7酶可以通过蛋白酶作用从目标泛素化蛋白质中去除泛素。